Login to Your Account



Other News To Note


Friday, April 27, 2012
• Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, said two leading health insurers in Switzerland agreed to fully reimburse the cost of Scenesse (afamelanotide 16-mg implant) for erythropoietic protoporphyria, a rare disease characterized by severe phototoxicity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription